Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% ...

Inclusion of pathogenic mechanisms in treatment design will allow future therapies to target-specific pathways involved in NAFLD pathogenesis. This review will focus on the current status of NAFLD ...

Discover the causes behind fatty liver disease, a condition affecting 25% of adults worldwide, and learn simple lifestyle ...

A deeper understanding of a gene that predisposes patients to fatty liver disease may open new avenues for treatment of the ...

It broadened our traditional understanding of how triglycerides and cholesterol are regulated during the progression of NAFLD." Currently, treatment options for NAFLD are limited; the main ...

Resmetirom significantly reduced liver stiffness in patients with compensated MASH cirrhosis, with a 6.7 kPa decrease over 2 years. The reduction in liver stiffness may lower the risk of liver ...

A new study suggests that beta blockers could reduce fat accumulation in the liver of mice genetically predisposed to ...

Doctors and experts gathered late last year in Bonifacio Global City to raise awareness on a “silent epidemic” that is ...